25 related articles for article (PubMed ID: 12462034)
1. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
[TBL] [Abstract][Full Text] [Related]
3. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
Xue SL; Wu DP; Sun AN; Tang XW
Am J Hematol; 2008 Feb; 83(2):167-70. PubMed ID: 17874449
[TBL] [Abstract][Full Text] [Related]
4. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Saito K
Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
6. [WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
Nakamura Y; Arai Y; Gunji H; Arai H; Nakamura F; Handa T; Tadokoro J; Maki K; Saito K; Mitani K
Rinsho Ketsueki; 2002 Oct; 43(10):960-2. PubMed ID: 12462034
[TBL] [Abstract][Full Text] [Related]
7. [Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
Yamato H; Yamada K; Koike T; Yoshida M; Tsunogake S; Aoyagi M; Nakamura Y; Watanabe K; Saito K; Enokihara H
Rinsho Ketsueki; 1995 Feb; 36(2):128-33. PubMed ID: 7536277
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
Wei G; Ni W; Chiao JW; Cai Z; Huang H; Liu D
J Hematol Oncol; 2011 Nov; 4():46. PubMed ID: 22082134
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Hennessy B; Giles F; Cortes J; O'brien S; Ferrajoli A; Ossa G; Garcia-Manero G; Faderl S; Kantarjian H; Verstovsek S
Am J Hematol; 2004 Nov; 77(3):209-14. PubMed ID: 15495258
[TBL] [Abstract][Full Text] [Related]
10. D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Zheng R; Xie B; Wang C; Yu B; Xu J; Tan H
Ann Hematol; 2016 Jan; 95(1):157-159. PubMed ID: 26382274
[No Abstract] [Full Text] [Related]
11. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.
Megías-Vericat JE; Herrero MJ; Rojas L; Montesinos P; Bosó V; Moscardó F; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2016 Feb; 16(1):30-40. PubMed ID: 26644203
[TBL] [Abstract][Full Text] [Related]
12. [Research Advances on Combination Strategies of Demethylating Agents for Elderly Acute Myeloid Leukemia--Review].
Sun WX; Jiang B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1339-1343. PubMed ID: 31418404
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
